Cargando…

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease

Amikacin is used as a therapy for patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) who are resistant to macrolide antibiotics or have severe symptoms. This study aimed to characterize the pharmacokinetic properties of amikacin in patients with NTM-PD by developing a population p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Xuanyou, Oh, Jaeseong, Cho, Joo-Youn, Lee, SeungHwan, Rhee, Su-jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694782/ https://www.ncbi.nlm.nih.gov/pubmed/33172135 http://dx.doi.org/10.3390/antibiotics9110784

Ejemplares similares

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
por: Aznar, Maria Luisa, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform
por: Kim, Byungwook, et al.
Publicado: (2021)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

Nontuberculous mycobacterial osteomyelitis
por: Bi, Sheng, et al.
Publicado: (2015)

A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2018)

A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2017)

Retraction and Republication: A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects
por: Jin, Xuanyou, et al.
Publicado: (2020)

Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet
por: Lee, Soyoung, et al.
Publicado: (2018)

Recurrent Bilateral Breast Abscess Due to Nontuberculous Mycobacterial Infection
por: Yoo, Hyunkyung, et al.
Publicado: (2014)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
por: Hwang, Sejung, et al.
Publicado: (2022)

Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective
por: Koh, Won-Jung, et al.
Publicado: (2005)

Recurrent Nontuberculous Mycobacterial Tenosynovitis
por: Kwan, Melissa, et al.
Publicado: (2021)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
por: Jang, Kyungho, et al.
Publicado: (2017)

Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease
por: Cowman, Steven A., et al.
Publicado: (2018)

SnackNTM: An Open-Source Software for Sanger Sequencing-based Identification of Nontuberculous Mycobacterial Species
por: Kim, Young-Gon, et al.
Publicado: (2022)

Pulmonary Chondroid Hamartoma With Nontuberculous Mycobacterial Infection: Two Case Reports
por: Lee, Yong Chul, et al.
Publicado: (2015)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
por: Kang, Jihyun, et al.
Publicado: (2021)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease
por: Ellis, Huw C., et al.
Publicado: (2023)

Management of pulmonary nontuberculous mycobacterial disease
por: Horan, Kathleen L, et al.
Publicado: (2009)

Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases
por: Wi, Yu Mi
Publicado: (2019)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
por: Oh, JungJin, et al.
Publicado: (2023)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomes
por: Kim, Hyung-Jun, et al.
Publicado: (2023)

Association of low fat mass with nontuberculous mycobacterial infection in patients with bronchiectasis
por: Lim, Sung Yoon, et al.
Publicado: (2021)

The Impact of Nontuberculous Mycobacteria Species on Mortality in Patients With Nontuberculous Mycobacterial Lung Disease
por: Wang, Ping-Huai, et al.
Publicado: (2022)

Prognosis of nontuberculous mycobacterial pulmonary disease according to the method of microbiologic diagnosis
por: Sin, Sooim, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022)

Nontuberculous Mycobacterial Pulmonary Diseases in Immunocompetent Patients
por: Koh, Won-Jung, et al.
Publicado: (2002)

Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
por: Kwon, Yong-Soo, et al.
Publicado: (2016)

Extrapulmonary Nontuberculous Mycobacterial Infections in Southern Arizona
por: Florita, Catalin, et al.
Publicado: (2017)

Hemophagocytic lymphohistiocytosis complicating nontuberculous mycobacterial infection
por: Gupta, Stuti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ancjudk1d9hmdspc8uniuc1gf2